Thuja Capital is an independent early-stage venture capital firm based in the Netherlands, specializing in investments in innovative life science and medical product companies across the Benelux region. The firm is currently investing out of its Thuja Capital Healthcare Fund III, which closed in December 2021 at EUR 76M (~USD 86M).
50% of their portfolio is in Biotech & Life Sciences. They made 1 investments in the last 12 months. Average disclosed round size is $20.2M (across 4 rounds with reported amounts).
Portfolio
12
Fund Size
$86M
Top Stage
Series A
Last 12 Mo
0
Team
Harrold van Barlingen
Managing Partner
Michel Briejer
Managing Partner
Evan Castiglia
Partner
Florian Ludwig
Venture Partner
Lisanne Blauw
Associate
Michel de Baar
Biotech Investor
Eleanor Price
Healthcare VC
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Salvia BioElectronics | Series B | $60M | May 2025 |
 Alesta Therapeutics | Series A | — | Jan 2025 |
 Artica Therapeutics | Pre-Seed | — | Jan 2023 |
 InnoSign | Series A | $8M | Jan 2022 |
 EsoBiotec | Unknown | $250K | Jan 2021 |
| IIndigo Diabetes | Series B | — | Jul 2020 |
 Tacalyx | Seed | — | Sep 2019 |
| AAlveron Pharma | Seed | — | Jan 2019 |
 Mellon Medical | Unknown | — | Oct 2017 |
| Mellon Medical | Unknown | — | Jan 2017 |
| NNightBalance | Series B | $12.5M | Jul 2016 |
 Fundamental Pharma | Seed | — | — |
 Gradient Denervation Technologies | Series A | — | — |
| IIndigo Diabetes | Series A | — | — |
Top Co-Investors
Last updated: 7 September 2026